The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HDFC Mutual Fund
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
HDFC Mutual Fund has disclosed an acquisition of 3,57,499 equity shares (0.13%) of Glenmark Pharmaceuticals through open market purchases on June 17, 2025. With this purchase, HDFC MF's aggregate holding across its various schemes rose from 4.94% to 5.07% of the company's paid-up equity share capital, crossing the 5% disclosure threshold under SEBI's SAST Regulations. The total paid-up equity capital of Glenmark stands at Rs. 28.22 crore, comprising 28.22 crore shares of Rs. 1 each. HDFC MF clarified it is not part of the promoter or promoter group.
This is a routine regulatory disclosure triggered by HDFC MF breaching the 5% shareholding mark, indicating continued institutional buying interest in Glenmark Pharmaceuticals. It is a positive signal of mutual fund confidence but not materially significant for stock price movement given the small incremental size.